On 21 October 2026 the Israeli microalgae company Brevel and India’s The Wave Group announced a 50/50 joint venture to build a 300,000-litre illuminated fermentation plant in Uttar Pradesh. The estimated investment is US$10–15 million. Divide one by the other and the plant is priced at roughly $33 to $50 per litre of vessel capacity.
That arithmetic is ours, not the companies’. And it is the part of the announcement that deserves caution, because nothing published alongside the number says what it covers: tanks, lights, building, land, downstream processing, or some subset. Without a scope, the figure is a headline, not a benchmark.
What was announced
The release and the three trade write-ups we read agree on the core facts.
| Item | As announced |
|---|---|
| Structure | 50/50 joint venture, signed in New Delhi |
| Site | Uttar Pradesh, north India, near The Wave Group’s sugar mills |
| Capacity | 300,000 litres in total |
| Estimated investment | US$10–15 million |
| Construction start | Later in 2026 |
| Full-scale production | Expected within 18 months |
| First product | Purallis, a clean-label chlorella ingredient |
| Feedstock | Sugar-mill side streams from The Wave Group |
| Technology | Brevel’s illuminated fermentation, described as covered by four patents |
| Existing Brevel capacity | One 5,000-litre bioreactor at its commercial site in Israel (per the release) |
Nutrition Insight describes the new plant as a 60-fold increase on the 5,000-litre vessel, which matches the arithmetic: 300,000 ÷ 5,000 = 60.
Illuminated fermentation is the point of difference. Sugar feeds the culture and light drives photosynthetic organisms such as chlorella to make compounds like chlorophyll and carotenoids, in a closed system. That matters for cost analysis because a conventional dark fermenter is a stirred tank and a lit one also needs a way to get light into the culture. The release does not say how the 300,000 litres are configured, so we cannot say whether it is a few large vessels or many small illuminated ones.
The $33–50 per litre figure, and why not to use it yet
Ten to fifteen million dollars across 300,000 litres is $33.33 to $50.00 per litre. For orientation, our recent analyses of other plants give a sense of how loosely “cost” is defined in this sector.
Danone and Michelin’s Biotech Open Platform was inaugurated in September 2026 with a first phase of more than €20m for a line of up to 15 m³ (11 m³ on the site’s own web page). Dividing naively gives about €1.33m per cubic metre, or roughly €1,330 per litre. We argued in that piece that the division is not an equipment cost, because the €20m covers a 5,000 m² site with purification and start-up costs. The same caveat applies in reverse here: Brevel’s number may be a narrow equipment figure, or it may be a full-plant figure, and the announcement does not say.
Set side by side, in nominal terms and before any euro-dollar conversion, the Open Platform’s naive figure is about 27 to 40 times Brevel’s. A gap of that size is not a finding about illuminated fermentation. It is a sign that the two numbers describe different things, or that one is wrong, or that the scale and process differ more than the headline suggests. Our earlier piece on China’s cheap-capacity claim made a related point: a capex number from the party selling or building the capacity, with no defined scope, is a hypothesis.
Practical consequence: do not drop $33–50 per litre into a scale-up model as an India-versus-Europe cost advantage. Treat it as the partners’ own estimate of an unspecified scope. If you are evaluating this capacity as a customer or co-investor, the first question is what the $10–15m includes, and the second is whether any of it is already spent.
Who is paying?
The sources describe the money differently.
- The release and Cultivated X say the joint venture is 50/50 and that the facility is funded by The Wave Group.
- Nutrition Insight says the $10–15m is funded by The Wave Group.
- Green Queen notes that “funded by The Wave Group” sits awkwardly beside a 50/50 structure and that the article does not explain how costs are split.
Both can be true. A partner can fund a facility and still hold half the equity if Brevel contributes technology and the patents. But the arithmetic of that arrangement is the interesting part: if Wave puts in all of $10–15m for 50%, the implied valuation of Brevel’s contribution is the same $10–15m, and we have no disclosure of how it was set. The announcement is silent.
Practical consequence: read “50/50” and “funded by Wave” as a question to put to the companies, not a settled structure. It determines who bears overruns.
Where the sources disagree on Brevel itself
Trade coverage of the announcement and the company’s own earlier press differ on several background facts. We list them because anyone doing diligence will meet all of them.
| Item | Version A | Version B |
|---|---|---|
| Brevel’s total funding | “USD 30M” (release) | $5M seed extension in early 2025 plus $1M from the Israel Innovation Authority (Green Queen); an $18.5m seed round completed in 2024 (AgFunderNews, February 2025) |
| Commercial plant opened | 2025 (release) | 2024 (Green Queen; vegconomist, February 2025) |
| Israeli plant size | One 5,000-litre bioreactor (release) | Illuminated fermenters at 50 L, 500 L and 5,000 L, in a 27,000 sq ft factory (Green Queen) |
| Israeli output | Not stated in the release | “Hundreds of tons of microalgae powder per year” (vegconomist, February 2025) |
These are not necessarily contradictions. A $30m total could include grants and the seed rounds together; a plant can be built in 2024 and commercially opened in 2025. But the Green Queen funding figures ($5m plus $1m) do not obviously reconcile with a $30m total or an $18.5m seed, and we have not found a source that reconciles them.
The offtake that exists
The only disclosed commercial commitment is older. In February 2025 Brevel signed a ten-year purchasing agreement with Israel’s CBC Group, under which Brevel supplies microalgae ingredients for functional beverages and dairy alternatives; CBC also took part in the funding. AgFunderNews reported a 60–70% protein concentrate in white powder form.
Neither the 2025 coverage nor the 2026 announcement gives volumes, minimum purchase commitments or pricing. vegconomist says explicitly that the investment amount, pricing and committed volumes are not disclosed. So the 300,000-litre plant is backed by one named ten-year purchasing agreement of unstated size, and the Israeli plant’s own utilisation is not published. Ayana Bio, a US plant-cell company, is named as a partner, and Cultivated X reports a $1.25 million BIRD Foundation grant with Ayana Bio from June 2026 to test whether light improves plant-cell growth; that is a research grant, not a purchase.
Practical consequence: capacity announcements are only as informative as the demand behind them. Until Brevel discloses volumes against the CBC agreement or names additional buyers, the plant is a 60x capacity bet on a product whose current market is a single disclosed counterparty.
The feedstock logic, and what it does not tell us
Locating the plant near The Wave Group’s sugar mills is a sound idea on its face: the companies say it cuts transport cost and uses side streams, and both say early trials with mill by-products gave “excellent” results and that the system is still being optimised. We covered the cost weight of the sugar input in our analysis of feedstock and yield, where yield, not sugar price, drove unit cost.
What is not published is the yield of chlorella biomass per kilogram of side-stream sugar, whether the side streams need pre-treatment, or whether light penetration limits culture density at 300,000 litres. Any of those could decide whether the plant makes Purallis at a price the food market will pay.
The counter-argument
The case for taking the figure seriously runs as follows, and none of it comes from the announcement: build costs in India may be lower than in Europe; a purpose-built, single-product plant avoids the cost of multi-product flexibility; and a partner with its own feedstock and a site near its own mills may carry costs a stand-alone developer would not. A low per-litre figure could also reflect simpler vessels than pharma-grade stainless. These are hypotheses we have not sourced, and we cannot rule any of them out.
But each of those is an argument for why the number might be plausible, and none is evidence about this plant. Until the companies define scope, the honest reading is that the figure is unverified in both directions.
What we could not establish
- What the $10–15 million covers. Equipment only, full plant, land, utilities, working capital, or phase one. No source says.
- Plant configuration. Number and size of vessels, how light is delivered, and whether 300,000 litres is working or nominal volume.
- Phasing. One trade headline, from a publication whose page our tools were blocked from reading, reportedly describes a 100,000-litre first phase. The release and the three pages we could read describe 300,000 litres with no phases. We have not relied on the unread claim and cannot confirm or rule it out.
- How the 50/50 structure and Wave’s funding fit together, and the valuation placed on Brevel’s contribution.
- Brevel’s funding history. The $30m, $18.5m and $5m-plus-$1m figures above are not reconciled in any source we read.
- Tonnage. How many tonnes of Purallis the plant is designed to produce, and at what biomass concentration.
- Pricing and committed volumes under the CBC agreement.
- When the 18 months start. The release language can be read as 18 months from the announcement or from the start of construction; “later in 2026” for the start would put full-scale production in 2028 on the second reading. This is our inference and the companies have not stated a date.
What to watch
- A definition of what the $10–15m covers, in a follow-up release or investor material.
- A construction start before the end of 2026, which is the companies’ own stated milestone.
- A named buyer or a volume figure for the Indian output.
- Disclosure of the Israeli plant’s actual annual output, which would test the “hundreds of tons” claim against a single disclosed 5,000-litre vessel.
- A rewritten figure: if the per-litre estimate is later restated with scope, compare it with the $33–50 above.